ZA200500323B - Use of lkb kinase inhibitors for the treatment of pain. - Google Patents

Use of lkb kinase inhibitors for the treatment of pain.

Info

Publication number
ZA200500323B
ZA200500323B ZA200500323A ZA200500323A ZA200500323B ZA 200500323 B ZA200500323 B ZA 200500323B ZA 200500323 A ZA200500323 A ZA 200500323A ZA 200500323 A ZA200500323 A ZA 200500323A ZA 200500323 B ZA200500323 B ZA 200500323B
Authority
ZA
South Africa
Prior art keywords
pain
treatment
kinase inhibitors
lkb
lkb kinase
Prior art date
Application number
ZA200500323A
Inventor
Martin Michaelis
Olaf Ritzeler
Gerhard Jaehne
Karl Rudolphi
Gerd Geisslinger
Hans-Georg Schaible
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of ZA200500323B publication Critical patent/ZA200500323B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
ZA200500323A 2002-08-17 2005-01-13 Use of lkb kinase inhibitors for the treatment of pain. ZA200500323B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (en) 2002-08-17 2002-08-17 Use of IKappaB kinase inhibitors in pain therapy

Publications (1)

Publication Number Publication Date
ZA200500323B true ZA200500323B (en) 2006-02-22

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200500323A ZA200500323B (en) 2002-08-17 2005-01-13 Use of lkb kinase inhibitors for the treatment of pain.

Country Status (34)

Country Link
EP (1) EP1531819B1 (en)
JP (1) JP4504811B2 (en)
KR (2) KR20110135428A (en)
CN (1) CN100398107C (en)
AR (1) AR043045A1 (en)
AT (1) ATE418336T1 (en)
AU (1) AU2003271555B2 (en)
BR (1) BR0313555A (en)
CA (1) CA2495455C (en)
CO (1) CO5690585A2 (en)
CR (1) CR7716A (en)
CY (1) CY1108874T1 (en)
DE (2) DE10237723A1 (en)
DK (1) DK1531819T3 (en)
EC (1) ECSP055609A (en)
ES (1) ES2320118T3 (en)
HK (1) HK1079426A1 (en)
HR (1) HRP20050041B1 (en)
IL (1) IL166780A (en)
MA (1) MA27334A1 (en)
MX (1) MXPA05001218A (en)
MY (1) MY138059A (en)
NO (1) NO334309B1 (en)
OA (1) OA12907A (en)
PL (1) PL212356B1 (en)
PT (1) PT1531819E (en)
RS (1) RS51878B (en)
RU (1) RU2320338C2 (en)
SI (1) SI1531819T1 (en)
TN (1) TNSN05044A1 (en)
TW (1) TWI325782B (en)
UA (1) UA80837C2 (en)
WO (1) WO2004022057A1 (en)
ZA (1) ZA200500323B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (en) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Thienopyridine for treating hepatitis C
DE102005025225A1 (en) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Process for the preparation of 2- (2-amino-pyrimidin-4-yl) -1H-indole-5-carboxylic acid derivatives
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
AR072297A1 (en) 2008-06-27 2010-08-18 Novartis Ag DERIVATIVES OF INDOL-2-IL-PIRIDIN-3-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE SYNTHESIS ALDOSTERONE.
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201242962A (en) 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HUE031525T2 (en) * 2011-12-06 2017-07-28 Sanofi Sa Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
JO3425B1 (en) * 2013-07-15 2019-10-20 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors
BR112016029044A2 (en) * 2014-07-03 2017-08-22 Sanofi Sa 2- (2-methylamino-pyrimidin-4-yl) -1h-indol-5-carboxylic acid [(s) -1-carbamoyl-2- (phenyl-pyrimidin-2-yl-amino) -ethyl] - amide for use in the treatment of osteoarthritis pain
CA3106124A1 (en) 2018-07-16 2020-01-23 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2261248C2 (en) * 1999-06-23 2005-09-27 Авентис Фарма Дойчланд Гмбх Substituted benzimidazoles and medicinal agent based on thereof
DE19951360A1 (en) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituted indoles
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase

Also Published As

Publication number Publication date
CN1674899A (en) 2005-09-28
MXPA05001218A (en) 2005-05-16
EP1531819B1 (en) 2008-12-24
TWI325782B (en) 2010-06-11
TW200417370A (en) 2004-09-16
PL212356B1 (en) 2012-09-28
WO2004022057A1 (en) 2004-03-18
IL166780A (en) 2011-11-30
KR20050058339A (en) 2005-06-16
KR20110135428A (en) 2011-12-16
AU2003271555A1 (en) 2004-03-29
UA80837C2 (en) 2007-11-12
ATE418336T1 (en) 2009-01-15
PT1531819E (en) 2009-02-18
CY1108874T1 (en) 2014-07-02
HRP20050041A2 (en) 2006-04-30
BR0313555A (en) 2005-07-12
HRP20050041B1 (en) 2013-07-31
CO5690585A2 (en) 2006-10-31
AR043045A1 (en) 2005-07-13
RU2320338C2 (en) 2008-03-27
KR101119845B1 (en) 2012-02-28
DE10237723A1 (en) 2004-07-08
DK1531819T3 (en) 2009-04-20
PL373568A1 (en) 2005-09-05
ES2320118T3 (en) 2009-05-19
HK1079426A1 (en) 2006-04-07
CA2495455A1 (en) 2004-03-18
SI1531819T1 (en) 2009-06-30
DE50310980D1 (en) 2009-02-05
JP4504811B2 (en) 2010-07-14
RS51878B (en) 2012-02-29
RU2005107419A (en) 2005-08-10
EP1531819A1 (en) 2005-05-25
OA12907A (en) 2006-10-13
MA27334A1 (en) 2005-05-02
CN100398107C (en) 2008-07-02
MY138059A (en) 2009-04-30
CR7716A (en) 2008-11-25
CA2495455C (en) 2011-01-11
NO334309B1 (en) 2014-02-03
RS20050070A (en) 2007-06-04
AU2003271555B2 (en) 2009-03-26
TNSN05044A1 (en) 2007-05-14
IL166780A0 (en) 2006-01-15
NO20051339L (en) 2005-05-03
JP2005539053A (en) 2005-12-22
ECSP055609A (en) 2005-04-18

Similar Documents

Publication Publication Date Title
ZA200500323B (en) Use of lkb kinase inhibitors for the treatment of pain.
EP1635813A4 (en) Combination therapy for the treatment of dyslipidemia
PL374700A1 (en) Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
AP2210A (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain.
HUS2200036I1 (en) Use of dihydroimidazolones for the treatment of dogs
AU2003300791A1 (en) Combination therapy for the treatment of pain
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
SI1627639T1 (en) Use of COX-2 inhibitors for the treatment of affective disorders
IL178827A0 (en) Use of reboxetine for the treatment of pain
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
HK1083732A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
AU2003268424A8 (en) Treatment of pain by inhibition of p38 map kinase
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
GB0213869D0 (en) The treatment of pain
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
GB2410744B (en) Kinase inhibitors for the treatment of disease
IL172101A0 (en) Use of indazole derivatives for the treatment of neuropathic pain
AU2003264297A1 (en) Use of vanilloid receptor antagonists for the treatment of pain
IL164951A0 (en) The treatment of pain with lfendropil
HK1087027A1 (en) Use of 2H-Ä1, 3Ü-oxazinoÄ3,2-AÜindole derivatives for the treatment of neuropathic pain
HK1062806A1 (en) Novel methods for the treatment and prevention of pain using stress- activated protein kinase inhibitors
GB0325957D0 (en) The treatment of pain